CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
LY2835219 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02256267
NCT02256267Phase 1Completed
CompareCT.gov

Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 3, 2014·Updated Jan 7, 2019

In Brief

A Phase 1 clinical trial evaluating LY2835219 and Rifampin for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration \[FDA\] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods. The study will last about 34 days. Screening is required within 28 days before study drug is given.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 3, 2014
Enrollment StartOct 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago

Interventions

LY2835219drug

Administered orally

Rifampindrug

Administered orally